Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer

With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Batoo, Sameer, Bayraktar, Soley, Al-Hattab, Eyad, Basu, Sandeep, Okuno, Scott, Glück, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961084/
https://www.ncbi.nlm.nih.gov/pubmed/31949426
http://dx.doi.org/10.4103/jcar.JCar_14_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961084/
https://www.ncbi.nlm.nih.gov/pubmed/31949426
http://dx.doi.org/10.4103/jcar.JCar_14_19

Ejemplares similares